Dimou et al Lai CL, Shouval D, Lok AS, et al. 2006b. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 354:1011–20. Lampertico P, Vigano M, Manenti E, et al. 2005. Five years of sequential LAM to LAM +ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepa- tocellular carcinoma. Hepatology, 42:582A. Lampertico P, Vigano M, Iavarone M, et al. 2006. Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years. Hepatology, 44:556A. Lau GKK, Piratvisuth T, Luo KX, et al. 2005. Peginterferon alfa-2a, lami- vudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 352:2682–95. Lee WM. 1997. Hepatitis B virus infection. N Engl J Med, 337:1733–45. Leung NWY, Lai CL, Chang TT, et al. 2001. Extended lamivudine treat- ment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology, 33:1527–32. Liaw YF, Leung NWY, Chang TT, et al. 2000. Effects of extended lamivu- dine therapy in Asian patients with chronic hepatitis B. Gastroenterol- ogy, 119:172–80. Liaw YF, Sung JJY, Chow WC, et al. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 351:1521–31. Lok AS, Heathcote EJ, Hoofnagle JH. 2001. Management of hepatitis B: 2000 summary of a workshop. Gastroenterology, 120:1828–53. Lok ASF, Lai CL, Leung N, et al. 2003. Long-term safety of Lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 125:1714–22. Maddrey WC. 2000. Hepatitis B: an important public health issue. J Med Virol, 61:362–6. Manesis E. and Hadziyannis S. 2001. Inteferon α treatment and retreat- ment of hepatitis B e negative chronic hepatitis B. Gastroenterology, 321:101–9. Marcellin P, Chang TT, Lim SG, et al. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitisB. N Engl J Med, 348:808–16. Marcellin P, Lau GKK, Bonino F, et al. 2004. Peginterferon alfa-2a alone, lamivudine alone and the two combination in patients with HBeAg- negative chronic hepatitis B. N Engl J Med, 351:1206–17. Marcellin P, Chang TT, Lim SG, et al. 2005. Increasing serologic, virologic and biochemical response over time to Adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients. J Hepatol, 42(2): S31–2. Marcellin P, Lau GKK, Farci P, et al. 2006. The majority of patients with HBeAg-negative chronic hepatitis B treated with Peginterferon alpha-2a (40KD) [PEGASYS] sustain responses 2 years post-treatment. J Hepatol, 44(2):S275. Niederaou C, Heintges T, Lange S, et al. 1996. Long term follow up of HBeAg positive patients treated with interferon alpha for chronic hepatitis B. N Engl J Med, 334:1422–7. Papatheodoridis GV, Manesis E, Hadziyannis SJ. 2001. The long-term outcome of interferon-a treated and untreated patients with HBeAg- negative chronic hepatitis B. J Hepatol, 34:306–13. Papatheodoridis GV, Dimou E, Laras A, et al. 2002. Course of virological breakthroughs under long-term lamivudine in HBeAg negative precore mutant HBV liver disease. Hepatology, 36:219–26. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. 2005. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology, 42:121–9. Peters MG, Hann HW, Martin P, et al. 2004. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitisB. Gastroenterology, 126:91–101. Rapti IN, Dimou E, Mitsoula P, Hadziyannis SJ. 2007. Combination of adefovir dipivoxil with lamivudine vs adefovir alone in lamivudine- resistant HBeAg-negative chronic hepatitis B patients. Hepatology, 45:307–13. Schiff E, Lee WM, Chao YC, et al. 2005. Efﬁcacy and safety of entecavir (ETV) and lamivudine (LVD) in compensated, cirrhotic patients with chronic hepatitis B. Hepatology, 42:583A. Sherman M, Yurdaydin C, Sollano J, et al. 2006. Entecavir for the treat- ment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology, 130:2039–49. Shouval D, Hatzis G, Kitis G, et al. 2006. Continued virologic and biochemi- cal improvement through 96 weeks of entecavir treatment in HBeAg(-) hepatitis B patients (Study ETV-027). J Hepatol, 44:S182. Tassopoulos NC, Volpes R, Pastore G, et al. 1999. Efﬁcacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology, 29:889–96. Tenney DJ, Levine SM, Rose RE, et al. 2004. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother, 48:3498–507. Thongsawat S, Lai CL, Gane G, et al. 2006. Telbivudine displays consistent antiviral efﬁcacy across patient subgroups for the treatment of chronic hepatitis B: results from the globe study. J Hepatol, 44:S49. Villet S, Pichoud C, Ollivet A, et al. 2005. Sequential antiviral therapy leads to the emergence of multiple drug resistant hepatitis B virus. Hepatology, 42:581A. Wong DKH, Cheung AM, O’Rourke K, et al. 1993. Effect of Alpha- Interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med, 119:312–23. Yim HJ, Hussain M, Liu Y, et al. 2006. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology, 44:703–12. Yurdaydin C, Sollano J, Hadziyannis SJ, et al. 2006. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory HBeAg (+) chronic hepatitis B patients (ETV-026). J Hepatol, 44:S36. 1086 Therapeutics and Clinical Risk Management 2007:3(6)